*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
*(incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1672)**

## VOLUNTARY ANNOUNCEMENT

# ASCLETIS SUBMITS IND APPLICATION TO THE U.S. FDA FOR ASC30_39 FDC, A POTENTIALLY FIRST-IN-CLASS ORAL SMALL MOLECULE FIXED-DOSE COMBINATION OF GLP-1R AGONIST AND SELECTIVE AMYLIN RECEPTOR AGONIST, FOR THE TREATMENT OF OBESITY

- *ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist ASC39, is the first co-formulation of an oral GLP-1 and an oral amylin to reach Investigational New Drug submission.*

- *ASC30_39 FDC demonstrated highly favorable pharmacokinetics with excellent oral bioavailability, high drug exposure and a long half-life.*

- *ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2).*

- *ASC39 demonstrated eloralintide-like amylin selectivity (40-fold for hAMY1R over hCTR) and efficacy in preclinical models.*

- *ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39, with room temperature stability and a small pill size.*

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist (SARA) ASC39, for the treatment of obesity.

"ASC30_39 FDC is the first co-formulation of an oral GLP-1 and an oral amylin to reach IND submission, combining two validated, complementary mechanisms for weight management in a single once-daily tablet." said Jinzi Jason Wu, Ph.D., Founder, Chairman of the Board and chief executive officer of Ascletis, "By pairing the potentially best-in-class efficacy and gastrointestinal tolerability of ASC30 with the first eloralintide-like oral small molecule amylin, we believe ASC30_39 FDC has the potential to offer patients a highly differentiated and convenient oral treatment option for obesity."

The IND submission builds upon the recent milestones of Ascletis' oral small molecule portfolio. ASC30 is currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2), enrolling approximately 4,600 participants with obesity or overweight in the U.S., Europe and Canada. Ascletis expects to report topline data from the AURORA Phase III clinical program in the third quarter of 2028. Ascletis recently announced the submission of an IND to the U.S. FDA for ASC39, its oral small molecule selective amylin receptor agonist, for the treatment of obesity.

**About ASC30_39 FDC**

Both ASC30 and ASC39 were discovered in-house utilizing Ascletis' Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) technology. ASC30_39 FDC was developed utilizing Ascletis' proprietary formulation technology and demonstrated excellent compatibility between ASC30 and ASC39, with room temperature stability and a small pill size.

Dosed orally in dogs, ASC30_39 FDC tablets demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key pharmacokinetic parameters of ASC30_39 FDC are consistent with those observed for the respective monotherapies in a head-to-head dog study. For further information, please refer to the announcement of the Company dated April 7, 2026.

ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2), and had a favorable gastrointestinal (GI) tolerability profile with half the rate of vomiting versus orforglipron when both drugs were dosed with weekly titration in non-head-to-head studies. For further information, please refer to the announcement of the Company dated December 8, 2025.

ASC39 is a potent oral small molecule selective amylin receptor agonist that was 40-fold more selective for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) and produced a 6.6% placebo-adjusted body weight reduction after once-daily oral administration for six consecutive days in diet-induced obese (DIO) rats, similar to eloralintide at 5.6%. For further information, please refer to the announcement of the Company dated March 17, 2026.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC30, ASC39 and/or ASC30_39 FDC successfully.

By order of the Board
**Ascletis Pharma Inc.**
**歌禮製藥有限公司**
**Jinzi Jason WU**
*Chairman*

Hong Kong
November 11, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*